In 1998, R2 transformed the practice of mammography by introducing the first FDA approved CAD solution for mammography. The ImageChecker® product line has since evolved and expanded, but some things never change.

Industry leading performance.

Our leading market position and long history allow us to leverage a formidable and growing database of clinical cases to effectively identify masses, architectural distortions, and micro calcifications in a diverse screening population.

R2 CAD is the only mammography CAD system that has been clinically validated via prospective studies to significantly improve detection performance without a significant increase in workup rates. Improvement in radiologist performance using R2 CAD was demonstrated via a prospective clinical trial and first published in 2000 (Freer et al.). Since then two additional independent, prospective sequential read studies on R2 CAD have shown that the use of the CAD resulted in the detection of 7.4% percent to 19.5% percent more cancers.

More than 25 peer reviewed clinical studies also validate the performance of R2’s ImageChecker mammography CAD.

• R2's CAD algorithm provides the best overall performance in the industry so you'll find more cancers and you'll find them earlier.
• R2 delivers the lowest false marker rate available, because sometimes the most important mark is no mark at all.